Hualan Vac(SZ:301207) Xin Lang Cai Jing·2025-09-16 01:41Core Viewpoint - Hualan Vaccine's stock experienced a decline of 1.24% on September 15, with a trading volume of 37.6 million yuan, indicating potential market volatility and investor sentiment shifts [1]. Financing and Margin Trading - On September 15, Hualan Vaccine had a financing buy-in amount of 4.11 million yuan and a financing repayment of 5.61 million yuan, resulting in a net financing outflow of 1.50 million yuan. The total financing and margin trading balance reached 115 million yuan, which is 1.04% of the circulating market value, indicating a relatively high level compared to the past year [1]. - The company had a margin trading activity on the same day, with 3,200 shares repaid and 400 shares sold short, amounting to a short sale value of 7,336 yuan. The remaining short selling volume was 22,100 shares, with a margin balance of 406,200 yuan, also reflecting a high level compared to the past year [1]. Financial Performance - For the first half of 2025, Hualan Vaccine reported a revenue of 59.96 million yuan, representing a year-on-year growth of 68.77%. However, the net profit attributable to shareholders decreased by 17.71% to 20.80 million yuan [2]. - Since its A-share listing, Hualan Vaccine has distributed a total of 680 million yuan in dividends, with 600 million yuan distributed over the past three years [3]. Shareholder Structure - As of August 10, the number of Hualan Vaccine shareholders decreased by 5.26% to 18,000, while the average circulating shares per person increased by 5.56% to 7,869 shares [2]. - As of June 30, 2025, the top ten circulating shareholders included various ETFs and investment funds, with notable changes in holdings among major shareholders, indicating shifts in institutional investment [3].